Feds Subpoena Cephalon Over Treanda Marketing
NEW YORK, Sept. 26, 2011 - In an SEC filing, Cephalon said it has received a subpoena from the DOJ requesting records regarding its marketing of leukemia drug Treanda. An excerpt of the filing is below.
On September 23, 2011, Cephalon, Inc. (the "Company")
received a subpoena duces tecum from the U.S. Attorney's Office for
the Southern District of New York pursuant to its authority under
the Health Insurance Portability and Accountability Act requesting
records regarding TREANDA® (bendamustine hydrochloride). The
Company is in the process of responding to the subpoena and intends
to cooperate fully.
Posted: September 2011